

S 1041

Affordable Prescriptions for Patients Act

Congress: 119 (2025–2027, Current)

Chamber: Senate

Policy Area: Commerce

Introduced: Mar 13, 2025

Current Status: Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.

Latest Action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 44. (Apr 10, 2025)

Official Text: <https://www.congress.gov/bill/119th-congress/senate-bill/1041>

Sponsor

Name: Sen. Cornyn, John [R-TX]

Party: Republican • **State:** TX • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Blumenthal, Richard [D-CT]	D · CT		Mar 13, 2025
Sen. Durbin, Richard J. [D-IL]	D · IL		Mar 13, 2025
Sen. Grassley, Chuck [R-IA]	R · IA		Mar 13, 2025

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Reported By	Apr 10, 2025

Subjects & Policy Tags

Policy Area:

Commerce

Related Bills

Bill	Relationship	Last Action
119 S 891	Related bill	Mar 6, 2025: Read twice and referred to the Committee on Finance.
119 HR 1768	Related bill	Mar 3, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, the Budget, the Judiciary, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Affordable Prescriptions for Patients Act

This bill limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug. (A biologic drug is produced through natural processes or isolated from natural sources. A biosimilar version is substantially similar to the original biologic, which is the reference product, and is often marketed as a less expensive alternative.)

The bill's provisions apply to an existing framework that gives the biosimilar manufacturer an abbreviated path to Food and Drug Administration approval to sell the biosimilar. Specifically, if the biosimilar manufacturer completes certain actions under the framework, such as sharing certain information about its product with the reference product manufacturer, the bill limits the number of certain patents that the reference product manufacturer may assert in a lawsuit, such as patents that were filed more than four years after the reference product received market approval. The limit shall not apply to patents claiming certain methods for using the biologic drug.

The court in which the infringement lawsuit is filed may increase the limit if justice so requires or if there is good cause for the increase.

